{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T07:23:37Z","timestamp":1790234617801,"version":"4.1.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T00:00:00Z","timestamp":1657843200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T00:00:00Z","timestamp":1657843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Drug resistance is a key factor in the treatment failure of acute myeloid leukemia (AML). Nuclear factor E2-related factor 2 (Nrf2) plays a crucial role in tumor chemotherapy resistance. However, the potential mechanism of Nrf2 regulating DNA mismatch repair (MMR) pathway to mediate gene-instability drug resistance in AML is still unclear. Here, it was found that Nrf2 expression was closely related to the disease progression of AML as well as highly expressed in AML patients with poor prognostic gene mutations. Meanwhile, it was also found that the expression of Nrf2 was significantly negatively correlated with DNA MMR gene replication factor C4 (RFC4) in AML. CHIP analysis combined with luciferase reporter gene results further showed that Nrf2 may inhibit the expression of RFC4 by its interaction with the RFC4 promoter. In vitro and vivo experiments showed that the overexpression of Nrf2 decreased the killing effect of chemotherapy drug cytarabine (Ara-C) on leukemia cells and inhibited the expression of RFC4. Mechanistically, The result that Nrf2-RFC4 axis mediated AML genetic instability drug resistance might be received by activating the JNK\/NF-\u03baB signaling pathway. Taken together, these findings may provide a new idea for improving AML drug resistance.<\/jats:p>","DOI":"10.1038\/s41417-022-00501-1","type":"journal-article","created":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T12:04:27Z","timestamp":1657886667000},"page":"1773-1790","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["RETRACTED ARTICLE: Nrf2 overexpression increases the resistance of acute myeloid leukemia to cytarabine by inhibiting replication factor C4"],"prefix":"10.1038","volume":"29","author":[{"given":"Tianzhen","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengyun","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianzhuo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8642-3447","authenticated-orcid":false,"given":"Weili","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5118-6990","authenticated-orcid":false,"given":"Jishi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9492-5204","authenticated-orcid":false,"given":"Qin","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,15]]},"reference":[{"key":"501_CR1","doi-asserted-by":"publisher","first-page":"3544","DOI":"10.1200\/JCO.2016.67.5892","volume":"34","author":"G Ganzel","year":"2016","unstructured":"Ganzel G, Manola J, Douer D, Rowe JM, Fernandez HF, Paietta EM, et al. Extramedullary disease in adult acute myeloid leukemia is common but lacks independent significance: analysis of patients in ECOG-ACRIN Cancer Research Group Trials, 1980-2008. J Clin Oncol. 2016;34:3544\u201353.","journal-title":"J Clin Oncol"},{"key":"501_CR2","doi-asserted-by":"publisher","first-page":"692800","DOI":"10.3389\/fcell.2021.692800","volume":"9","author":"KE Miari","year":"2021","unstructured":"Miari KE, Guzman ML, Wheadon H, Williams MTS. Macrophages in acute myeloid leukaemia: significant players in therapy resistance and patient outcomes. Front Cell Dev Biol. 2021;9:692800.","journal-title":"Front Cell Dev Biol."},{"key":"501_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s11864-017-0456-2","volume":"18","author":"P Bose","year":"2017","unstructured":"Bose P, Vachhani P, Cortes J. Treatment of relapsed\/refractory acute myeloid leukemia. Curr Treat Options Oncol. 2017;18:17.","journal-title":"Curr Treat Options Oncol"},{"key":"501_CR4","first-page":"467","volume":"29","author":"RF Schlenk","year":"2017","unstructured":"Schlenk RF, M\u00fcller-Tidow C, Benner A, Kieser M. Relapsed\/refractory acute myeloid leukemia: any progress? Treat Options Oncol. 2017;29:467\u201373.","journal-title":"Treat Options Oncol"},{"key":"501_CR5","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1182\/blood-2014-10-551911","volume":"126","author":"F Thol","year":"2015","unstructured":"Thol F, Schlenk RF, Heuser M, Ganser A. How I treat refractory and early relapsed acute myeloid leukemia. Blood 2015;126:319\u201327.","journal-title":"Blood"},{"key":"501_CR6","doi-asserted-by":"publisher","first-page":"3126","DOI":"10.1158\/1535-7163.MCT-10-0397","volume":"9","author":"KE Allen","year":"2010","unstructured":"Allen KE, Weiss GJ. Resistance may not be futile: microRNA biomarkers for chemoresistance and potential therapeutics. Mol Cancer Ther. 2010;9:3126\u201336.","journal-title":"Mol Cancer Ther"},{"key":"501_CR7","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s00280-009-1200-9","volume":"66","author":"SM Nathwani","year":"2010","unstructured":"Nathwani SM, Butler S, Fayne D, McGovern NN, Sarkadi B, Meegan MJ, et al. Novel microtubule-targeting agents, pyrrolo-1,5-benzoxazepines, induce apoptosis in multi-drug-resistant cancer cells. Cancer Chemother Pharm. 2010;66:585\u201396.","journal-title":"Cancer Chemother Pharm"},{"key":"501_CR8","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1038\/nrd3253","volume":"9","author":"C Dumontet","year":"2010","unstructured":"Dumontet C, Jordan MA. Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov. 2010;9:790\u2013803.","journal-title":"Nat Rev Drug Discov"},{"key":"501_CR9","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.3324\/haematol.2010.031823","volume":"96","author":"C Marzac","year":"2011","unstructured":"Marzac C, Garrido E, Tang X, Fava F, Hirsch P, De Benedictis C, et al. ATP Binding Cassette transporters associated with chemoresistance: transcriptional profiling in extreme cohorts and their prognostic impact in a cohort of 281 acute myeloid leukemia patients. Haematologica 2011;96:1293\u2013301.","journal-title":"Haematologica"},{"key":"501_CR10","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.pharmthera.2018.10.009","volume":"195","author":"R Yamaguchi","year":"2019","unstructured":"Yamaguchi R, Lartigue L, Perkins G. Targeting Mcl-1 and other Bcl-2 family member proteins in cancer therapy. Pharm Ther. 2019;195:13\u201320.","journal-title":"Pharm Ther"},{"key":"501_CR11","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1182\/blood-2018-03-828269","volume":"132","author":"M Konopleva","year":"2018","unstructured":"Konopleva M, Letai A. BCL-2 inhibition in AML: an unexpected bonus? Blood 2018;132:1007\u201312.","journal-title":"Blood"},{"key":"501_CR12","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1111\/febs.13633","volume":"283","author":"W Wu","year":"2016","unstructured":"Wu W, Ma D, Wang P, Cao L, Lu T, Fang Q, et al. Potential crosstalk of the interleukin-6-heme oxygenase-1-dependent mechanism involved in resistance to lenalidomide in multiple myeloma cells. FEBS J. 2016;283:834\u201349.","journal-title":"FEBS J"},{"key":"501_CR13","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.biopha.2017.04.076","volume":"91","author":"P Liu","year":"2017","unstructured":"Liu P, Ma D, Yu Z, Zhe N, Ren M, Wang P, et al. Overexpression of heme oxygenase-1 in bone marrow stromal cells promotes microenvironment-mediated imatinib resistance in chronic myeloid leukemia. Biomed Pharmacother. 2017;91:21\u201330.","journal-title":"Biomed Pharmacother"},{"key":"501_CR14","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/s41375-018-0279-6","volume":"33","author":"B Yan","year":"2019","unstructured":"Yan B, Chen Q, Shimada K, Tang M, Li H, Gurumurthy A, et al. Histone deacetylase inhibitor targets CD123\/CD47-positive cells and reverse chemoresistance phenotype in acute myeloid leukemia. Leukemia 2019;33:931\u201344.","journal-title":"Leukemia"},{"key":"501_CR15","doi-asserted-by":"publisher","first-page":"51.","DOI":"10.1186\/s13045-017-0416-0","volume":"10","author":"H Hackl","year":"2017","unstructured":"Hackl H, Astanina K, Wieser R. Molecular and genetic alterations associated with therapy resistance and relapse of acute myeloid leukemia. J Hematol Oncol. 2017;10:51.","journal-title":"J Hematol Oncol"},{"key":"501_CR16","first-page":"644","volume":"168","author":"A Tubbs","year":"2017","unstructured":"Tubbs A, Nussenzweig A. Endogenous DNA, Damage as a source of genomic instability in cancer. Cancer Cell. 2017;168:644\u201356.","journal-title":"Cancer Cell"},{"key":"501_CR17","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/S0140-6736(18)31041-9","volume":"392","author":"NJ Short","year":"2018","unstructured":"Short NJ, Rytting ME, Cortes JE. Acute myeloid leukaemia. Lancet. 2018;392:593\u2013606.","journal-title":"Lancet"},{"key":"501_CR18","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s13045-020-00992-1","volume":"13","author":"MT Gebru","year":"2020","unstructured":"Gebru MT, Wang HG. Therapeutic targeting of FLT3 and associated drug resistance in acute myeloid leukemia. J Hematol Oncol. 2020;13:155.","journal-title":"J Hematol Oncol"},{"key":"501_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00425-3","volume":"11","author":"H Kantarjian","year":"2021","unstructured":"Kantarjian H, Kadia T, DiNardo C, Daver N, Borthakur G, Jabbour E, et al. Acute myeloid leukemia: current progress and future directions. Blood Cancer J. 2021;11:41.","journal-title":"Blood Cancer J."},{"key":"501_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00497-1","volume":"11","author":"GC Issa","year":"2021","unstructured":"Issa GC, DiNardo CD. Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm. Blood Cancer J. 2021;11:107.","journal-title":"Blood Cancer J"},{"key":"501_CR21","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1111\/cas.13537","volume":"109","author":"H Kitamura","year":"2018","unstructured":"Kitamura H, Motohashi H. NRF2 addiction in cancer cells. Cancer Sci. 2018;109:900\u201311.","journal-title":"Cancer Sci."},{"key":"501_CR22","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ccell.2018.03.022","volume":"34","author":"M Rojo De La Vega","year":"2018","unstructured":"Rojo De La Vega M, Chapman E, Zhang DD. NRF2 and the hallmarks of cancer. Cancer Cell. 2018;34:21\u201343.","journal-title":"Cancer Cell"},{"key":"501_CR23","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.freeradbiomed.2013.06.041","volume":"65","author":"I Ga\u00f1\u00e1n-G\u00f3mez","year":"2013","unstructured":"Ga\u00f1\u00e1n-G\u00f3mez I, Wei Y, Yang H, Boyano-Ad\u00e1nez MC, Garc\u00eda-Manero G. Oncogenic functions of the transcription factor Nrf2. Free Radic Biol Med. 2013;65:750\u201364.","journal-title":"Free Radic Biol Med"},{"key":"501_CR24","doi-asserted-by":"publisher","first-page":"541.","DOI":"10.3390\/cancers13030541","volume":"13","author":"H Sekine","year":"2021","unstructured":"Sekine H, Motohashi H. Roles of CNC transcription factors NRF1 and NRF2 in cancer. Cancers (Basel). 2021;13:541.","journal-title":"Cancers (Basel)"},{"key":"501_CR25","doi-asserted-by":"publisher","first-page":"485","DOI":"10.3324\/haematol.2018.197749","volume":"104","author":"P Lin","year":"2019","unstructured":"Lin P, Ren Y, Yan X, Kesarwani M, Bu J, Zhan D, et al. The high NRF2 expression confers chemotherapy resistance partly through up-regulated DUSP1 in myelodysplastic syndromes. Haematologica 2019;104:485\u201396.","journal-title":"Haematologica"},{"key":"501_CR26","doi-asserted-by":"publisher","first-page":"e177227","DOI":"10.1371\/journal.pone.0177227","volume":"12","author":"S Karathedath","year":"2017","unstructured":"Karathedath S, Rajamani BM, Musheer Aalam SM, Luo Y, Zhang H, Kesarwani M, et al. Role of NF-E2 related factor 2 (Nrf2) on chemotherapy resistance in acute myeloid leukemia (AML) and the effect of pharmacological inhibition of Nrf2. PLoS ONE. 2017;12:e177227.","journal-title":"PLoS ONE"},{"key":"501_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2017.176","volume":"8","author":"B Xu","year":"2017","unstructured":"Xu B, Wang S, Li R, Chen K, He L, Deng M, et al. Disulfiram\/copper selectively eradicates AML leukemia stem cells in vitro and in vivo by simultaneous induction of ROS-JNK and inhibition of NF-\u03baB and Nrf2. Cell Death Dis. 2017;8:e2797.","journal-title":"Cell Death Dis"},{"key":"501_CR28","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1038\/ng.3991","volume":"49","author":"J Frigola","year":"2017","unstructured":"Frigola J, Sabarinathan R, Mularoni L, Mui\u00f1os F, Gonzalez-Perez A, L\u00f3pez-Bigas N. Reduced mutation rate in exons due to differential mismatch repair. Nat Genet. 2017;49:1684\u201392.","journal-title":"Nat Genet"},{"key":"501_CR29","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/nrg2268","volume":"9","author":"A Aguilera","year":"2008","unstructured":"Aguilera A, G\u00f3mez-Gonz\u00e1lez B. Genome instability: a mechanistic view of its causes and consequences. Nat Rev Genet. 2008;9:204\u201317.","journal-title":"Nat Rev Genet"},{"key":"501_CR30","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1158\/2159-8290.CD-16-1179","volume":"7","author":"S Haricharan","year":"2017","unstructured":"Haricharan S, Punturi N, Singh P, Holloway KR, Anurag M, Schmelz J, et al. Loss of mutl disrupts CHK2-dependent cell-cycle control through CDK4\/6 to promote intrinsic endocrine therapy resistance in primary breast cancer. Cancer Discov. 2017;7:1168\u201383.","journal-title":"Cancer Discov."},{"key":"501_CR31","first-page":"1343","volume":"8","author":"Y Li","year":"2018","unstructured":"Li Y, Gan S, Ren L, Yuan L, Liu J, Wang W, et al. Multifaceted regulation and functions of replication factor C family in human cancers. Am J Cancer Res. 2018;8:1343\u201355.","journal-title":"Am J Cancer Res"},{"key":"501_CR32","doi-asserted-by":"publisher","first-page":"R873","DOI":"10.1016\/j.cub.2003.10.048","volume":"13","author":"J Kim","year":"2003","unstructured":"Kim J, MacNeill SA. Genome stability: a new member of the RFC family. Curr Biol. 2003;13:R873\u20135.","journal-title":"Curr Biol"},{"key":"501_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10376-w","volume":"10","author":"MS Kang","year":"2019","unstructured":"Kang MS, Ryu E, Lee SW, Park J, Ha NY, Ra JS, et al. Regulation of PCNA cycling on replicating DNA by RFC and RFC-like complexes. Nat Commun. 2019;10:2420.","journal-title":"Nat Commun"},{"key":"501_CR34","doi-asserted-by":"publisher","first-page":"7096","DOI":"10.1073\/pnas.1324036111","volume":"111","author":"X Li","year":"2014","unstructured":"Li X, Liu L, Yang S, Song N, Zhou X, Gao J, et al. Histone demethylase KDM5B is a key regulator of genome stability. Proc Natl Acad. Sci. USA. 2014;111:7096\u2013101.","journal-title":"Proc Natl Acad. Sci. USA"},{"key":"501_CR35","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1038\/nm.2430","volume":"17","author":"B Diouf","year":"2011","unstructured":"Diouf B, Cheng Q, Krynetskaia NF, Yang W, Cheok M, Pei D, et al. Somatic deletions of genes regulating MSH2 protein stability cause DNA mismatch repair deficiency and drug resistance in human leukemia cells. Nat Med. 2011;17:1298\u2013303.","journal-title":"Nat Med"},{"key":"501_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-03331-x","volume":"12","author":"P Liu","year":"2021","unstructured":"Liu P, Ma D, Wang P, Pan C, Fang Q, Wang JS. Nrf2 overexpression increases risk of high tumor mutation burden in acute myeloid leukemia by inhibiting MSH2. Cell Death Dis. 2021;12:20.","journal-title":"Cell Death Dis"},{"key":"501_CR37","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.leukres.2015.02.009","volume":"39","author":"XJ Lin","year":"2015","unstructured":"Lin XJ, Fang Q, Chen SY, Zhe NN, Chai QX, Yu MS, et al. Heme oxygenase-1 suppresses the apoptosis of acute myeloid leukemia cells via the JNK\/c-JUN signaling pathway. Leuk Res. 2015;39:544\u201352.","journal-title":"Leuk Res"},{"key":"501_CR38","doi-asserted-by":"publisher","first-page":"5188","DOI":"10.1182\/blood-2012-04-422121","volume":"120","author":"SA Rushworth","year":"2012","unstructured":"Rushworth SA, Zaitseva L, Murray MY, Shah NM, Bowles KM, MacEwan DJ. The high Nrf2 expression in human acute myeloid leukemia is driven by NF-\u03baB and underlies its chemo-resistance. Blood. 2012;120:5188\u201398.","journal-title":"Blood"},{"key":"501_CR39","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1080\/10428190290006053","volume":"43","author":"T Robak","year":"2002","unstructured":"Robak T, Wrzesie\u0144-Ku\u015b A. The search for optimal treatment in relapsed and refractory acute myeloid leukemia. Leuk Lymphoma. 2002;43:281\u201391.","journal-title":"Leuk Lymphoma"},{"key":"501_CR40","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13046-020-01565-3","volume":"39","author":"JE Jang","year":"2020","unstructured":"Jang JE, Eom JI, Jeung HK, Chung H, Kim YR, Kim JS, et al. PERK\/NRF2 and autophagy form a resistance mechanism against G9a inhibition in leukemia stem cells. J Exp Clin Cancer Res. 2020;39:66.","journal-title":"J Exp Clin Cancer Res"},{"key":"501_CR41","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/cdd.2014.152","volume":"22","author":"NM Shah","year":"2015","unstructured":"Shah NM, Zaitseva L, Bowles KM, MacEwan DJ, Rushworth SA. NRF2-driven miR-125B1 and miR-29B1 transcriptional regulation controls a novel anti-apoptotic miRNA regulatory network for AML survival. Cell Death Differ. 2015;22:654\u201364.","journal-title":"Cell Death Differ"},{"key":"501_CR42","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.bbamcr.2018.02.010","volume":"1865","author":"I Bellezza","year":"2018","unstructured":"Bellezza I, Giambanco I, Minelli A, Donato R. Nrf2-Keap1 signaling in oxidative and reductive stress. Biochim Biophys Acta Mol Cell Res. 2018;1865:721\u201333.","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"501_CR43","doi-asserted-by":"publisher","first-page":"267","DOI":"10.3389\/fnins.2020.00267","volume":"14","author":"X Song","year":"2020","unstructured":"Song X, Long D. Nrf2 and ferroptosis: a new research direction for neurodegenerative diseases. Front Neurosci. 2020;14:267.","journal-title":"Front Neurosci"},{"key":"501_CR44","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s12265-020-10083-8","volume":"14","author":"R Vashi","year":"2021","unstructured":"Vashi R, Patel BM. NRF2 in cardiovascular diseases: a ray of hope! J Cardiovasc Transl Res. 2021;14:573\u201386.","journal-title":"J Cardiovasc Transl Res"},{"key":"501_CR45","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/hep.28251","volume":"63","author":"X Sun","year":"2016","unstructured":"Sun X, Ou Z, Chen R, Niu X, Chen D, Kang R, et al. Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells. Hepatology. 2016;63:173\u201384.","journal-title":"Hepatology."},{"key":"501_CR46","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.bbadis.2016.11.005","volume":"1863","author":"SM Ahmed","year":"2017","unstructured":"Ahmed SM, Luo L, Namani A, Wang XJ, Tang X. Nrf2 signaling pathway: pivotal roles in inflammation. Biochim Biophys Acta Mol Basis Dis. 2017;1863:585\u201397.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"501_CR47","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1146\/annurev-cancerbio-041916-065808","volume":"1","author":"CR Reczek","year":"2017","unstructured":"Reczek CR, Chandel NS. The two faces of reactive oxygen species in cancer. Annu Rev Cancer Biol. 2017;1:79\u201398.","journal-title":"Annu Rev Cancer Biol"},{"key":"501_CR48","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.freeradbiomed.2013.10.819","volume":"67","author":"HK Na","year":"2014","unstructured":"Na HK, Surh YJ. Oncogenic potential of Nrf2 and its principal target protein heme oxygenase-1. Free Radic Biol Med. 2014;67:353\u201365.","journal-title":"Free Radic Biol Med"},{"key":"501_CR49","doi-asserted-by":"publisher","first-page":"5486","DOI":"10.1158\/0008-5472.CAN-10-0713","volume":"70","author":"T Jiang","year":"2010","unstructured":"Jiang T, Chen N, Zhao F, Wang XJ, Kong B, Zheng W, et al. High levels of Nrf2 determine chemoresistance in type II endometrial cancer. Cancer Res. 2010;70:5486\u201396.","journal-title":"Cancer Res"},{"key":"501_CR50","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1002\/path.2653","volume":"220","author":"YR Kim","year":"2010","unstructured":"Kim YR, Oh JE, Kim MS, Kang MR, Park SW, Han JY, et al. Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin. J Pathol. 2010;220:446\u201351.","journal-title":"J Pathol"},{"key":"501_CR51","doi-asserted-by":"publisher","first-page":"3743","DOI":"10.1158\/1078-0432.CCR-09-3352","volume":"16","author":"LM Solis","year":"2010","unstructured":"Solis LM, Behrens C, Dong W, Suraokar M, Ozburn NC, Moran CA, et al. Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features. Clin Cancer Res. 2010;16:3743\u201353.","journal-title":"Clin Cancer Res"},{"key":"501_CR52","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1101\/gad.225680.113","volume":"27","author":"MC Jaramillo","year":"2013","unstructured":"Jaramillo MC, Zhang DD. The emerging role of the Nrf2\u2013Keap1 signaling pathway in cancer. Genes Dev. 2013;27:2179\u201391.","journal-title":"Genes Dev"},{"key":"501_CR53","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/gtc.12165","volume":"19","author":"Y Hirotsu","year":"2014","unstructured":"Hirotsu Y, Higashi C, Fukutomi T, Katsuoka F, Tsujita T, Yagishita Y, et al. Transcription factor NF-E2-related factor 1 impairs glucose metabolism in mice. Genes Cells. 2014;19:650\u201365.","journal-title":"Genes Cells"},{"key":"501_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22625-y","volume":"12","author":"TR Docking","year":"2021","unstructured":"Docking TR, Parke RJ, J\u00e4dersten M, Swanson LA, Chan SK, Chiu R, et al. A clinical transcriptome approach to patient stratification and therapy selection in acute myeloid leukemia. Nat Commun. 2021;12:2474.","journal-title":"Nat Commun"},{"key":"501_CR55","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H D\u00f6hner","year":"2015","unstructured":"D\u00f6hner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N. Engl J Med. 2015;373:1136\u201352.","journal-title":"N. Engl J Med"},{"key":"501_CR56","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.cell.2010.05.002","volume":"141","author":"AA Larrea","year":"2010","unstructured":"Larrea AA, Lujan SA, Kunkel TA. SnapShot: DNA mismatch repair. Cell 2010;141:730\u20131.","journal-title":"Cell"},{"key":"501_CR57","doi-asserted-by":"publisher","first-page":"3580719.","DOI":"10.1155\/2020\/3580719","volume":"2020","author":"Q Ju","year":"2020","unstructured":"Ju Q, Li X, Zhang H, Yan S, Li Y, Zhao Y. NFE2L2 is a potential prognostic biomarker and is correlated with immune infiltration in brain lower grade glioma: a pan-cancer analysis. Oxid Med Cell Longev. 2020;2020:3580719.","journal-title":"Oxid Med Cell Longev"},{"key":"501_CR58","doi-asserted-by":"publisher","first-page":"107664","DOI":"10.1016\/j.pharmthera.2020.107664","volume":"217","author":"Y Liu","year":"2021","unstructured":"Liu Y, Lang F, Yang C. NRF2 in human neoplasm: cancer biology and potential therapeutic target. Pharm Ther. 2021;217:107664.","journal-title":"Pharm Ther"},{"key":"501_CR59","doi-asserted-by":"publisher","first-page":"4567","DOI":"10.1158\/1078-0432.CCR-18-3735","volume":"25","author":"XC Wang","year":"2019","unstructured":"Wang XC, Yue X, Zhang RX, Liu TY, Pan ZZ, Yang MJ, et al. Genome-wide RNAi screening identifies RFC4 as a factor that mediates radioresistance in colorectal cancer by facilitating nonhomologous end joining repair. Clin Cancer Res. 2019;25:4567\u201379.","journal-title":"Clin Cancer Res"},{"key":"501_CR60","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1111\/j.1745-7254.2007.00579.x","volume":"28","author":"J Cui","year":"2007","unstructured":"Cui J, Zhang M, Zhang YQ, Xu ZH. JNK pathway: diseases and therapeutic potential. Acta Pharm Sin. 2007;28:601\u20138.","journal-title":"Acta Pharm Sin"},{"key":"501_CR61","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1002\/med.21574","volume":"39","author":"Q Wu","year":"2019","unstructured":"Wu Q, Wu W, Fu B, Shi L, Wang X, Kuca K. JNK signaling in cancer cell survival. Med Res Rev. 2019;39:2082\u2013104.","journal-title":"Med Res Rev"},{"key":"501_CR62","doi-asserted-by":"publisher","first-page":"6245","DOI":"10.1038\/onc.2008.301","volume":"27","author":"DN Dhanasekaran","year":"2008","unstructured":"Dhanasekaran DN, Reddy EP. JNK signaling in apoptosis. Oncogene. 2008;27:6245\u201351.","journal-title":"Oncogene."},{"key":"501_CR63","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1038\/leu.2008.192","volume":"22","author":"ED Lagadinou","year":"2008","unstructured":"Lagadinou ED, Ziros PG, Tsopra OA, Dimas K, Kokkinou D, Thanopoulou E, et al. c-Jun N-terminal kinase activation failure is a new mechanism of anthracycline resistance in acute myeloid leukemia. Leukemia. 2008;22:1899\u2013908.","journal-title":"Leukemia."}],"updated-by":[{"DOI":"10.1038\/s41417-022-00519-5","type":"correction","label":"Correction","source":"retraction-watch","updated":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T00:00:00Z","timestamp":1661731200000},"record-id":"67785"},{"DOI":"10.1038\/s41417-022-00519-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T00:00:00Z","timestamp":1661731200000}},{"DOI":"10.1038\/s41417-025-00913-9","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"record-id":"67786"},{"DOI":"10.1038\/s41417-025-00913-9","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000}}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41417-022-00501-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-022-00501-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-022-00501-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T11:02:45Z","timestamp":1746702165000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41417-022-00501-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,15]]},"references-count":63,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["501"],"URL":"https:\/\/doi.org\/10.1038\/s41417-022-00501-1","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41417-022-00519-5","asserted-by":"object"}]},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,15]]},"assertion":[{"value":"19 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2022","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41417-022-00519-5","URL":"https:\/\/doi.org\/10.1038\/s41417-022-00519-5","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2025","order":9,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":10,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article has been retracted. Please see the Retraction Notice for more detail:","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41417-025-00913-9","URL":"https:\/\/doi.org\/10.1038\/s41417-025-00913-9","order":12,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The present study gained approval from the Institutional Research Ethics Committee. Each patient provided the informed consent for participation. Mouse tests gained approval from the Animal Care and Use Committee in Guizhou Medical University, China.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}